Product Data Sheet

Utreloxastat

Cat. No.: HY-132845 CAS No.: 1213269-96-5

Molecular Formula: $C_{18}H_{28}O_2$ Molecular Weight: 276.41

Target: α-synuclein

Pathway: Neuronal Signaling

Storage: Powder -20°C 3 years

In solvent

4°C 2 years -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (180.89 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.6178 mL	18.0891 mL	36.1781 mL
	5 mM	0.7236 mL	3.6178 mL	7.2356 mL
	10 mM	0.3618 mL	1.8089 mL	3.6178 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: corn oil Solubility: 66.67 mg/mL (241.20 mM); Clear solution; Need ultrasonic and warming and heat to 49.6°C
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (4.52 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 1.25 mg/mL (4.52 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Utreloxastat (PTC857) is a compound used for the research of the disorders including α -synucleinopathies, tauopathies, Amyotrophic lateral sclerosis (ALS), traumatic brain injury, and ischemic-reperfusion related injuries (patent WO2020081879A2, example A1)^[1].

REFERENCES

[1]. Andrew W. Hinman, et al. 2,3,5-T OTHER DISORDERS. WO2020081879		(A-2,5-DIENE-1,4-DIONE FOR S	UPPRESSING AND TREATING $lpha$ -SY	NUCLEINOPATHIES, TAUOPATHIES, AND		
Caution: Product has not been fully validated for medical applications. For research use only.						
Te		Fax: 609-228-5909 Park Dr, Suite Q, Monmouth	E-mail: tech@MedChemExpre	ess.com		
	7.44.000.2.2.000.		3			

Page 2 of 2 www.MedChemExpress.com